ZL-1310 + atezolizumab + carboplatin

This is an investigational **combination therapy** consisting of the DLL3-targeted antibody-drug conjugate ZL-1310, the anti–PD-L1 immune checkpoint inhibitor atezolizumab, and the DNA-damaging platinum chemotherapy carboplatin. - **ZL-1310** is an antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3) on tumor cells, delivering a potent cytotoxic payload directly to cancer cells. It is being developed primarily for extensive-stage small cell lung cancer (ES-SCLC), where it has shown promising efficacy and manageable toxicity in early-phase trials[1][3]. - **Atezolizumab** is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), blocking an immune checkpoint and augmenting anti-tumor immune response. It is approved for several cancers including SCLC and triple-negative breast cancer, both as monotherapy and in combination with chemotherapy[2]. - **Carboplatin** is a platinum-based chemotherapy that induces DNA damage leading to apoptosis, widely used as a standard cytotoxic regimen in SCLC and other cancers[2]. This combination is in clinical development, evaluating synergy between targeted (DLL3), immune checkpoint inhibition (PD-L1), and chemotherapy in ES-SCLC.

Other names

ZL-1310 + atezolizumab + carboplatin